Phase IIa trial to evaluate two different doses of AQX 1125 in volunteers exposed to an environmental inflammatory stimulus
Phase of Trial: Phase II
Latest Information Update: 05 Apr 2013
At a glance
- Drugs Rosiptor (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
- 03 Apr 2013 Primary endpoint 'Inflammatory-markers' has been met according to an Aquinox media release.
- 15 Nov 2011 Planned End Date changed to 31 Dec 2012.
- 14 Nov 2011 New trial record